Iloperidone in the treatment of schizophrenia: an evidence-based review of its place in therapy
(Source: Core Evidence)
Source: Core Evidence - December 13, 2016 Category: Drugs & Pharmacology Tags: Core Evidence Source Type: research

Imiglucerase in the management of Gaucher disease type 1: an evidence-based review of its place in therapy
(Source: Core Evidence)
Source: Core Evidence - October 14, 2016 Category: Drugs & Pharmacology Tags: Core Evidence Source Type: research

Everolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapy
(Source: Core Evidence)
Source: Core Evidence - September 1, 2016 Category: Drugs & Pharmacology Tags: Core Evidence Source Type: research

Pirfenidone in the treatment of idiopathic pulmonary fibrosis: an evidence-based review of its place in therapy
(Source: Core Evidence)
Source: Core Evidence - June 30, 2016 Category: Drugs & Pharmacology Tags: Core Evidence Source Type: research

Azilsartan medoxomil in the management of hypertension: an evidence-based review of its place in therapy
(Source: Core Evidence)
Source: Core Evidence - April 4, 2016 Category: Drugs & Pharmacology Tags: Core Evidence Source Type: research

Azilsartan medoxomil in the management of hypertension: an evidence-based review of its place in therapy
Conclusion: Azilsartan is a safe and effective treatment option for every stage of hypertension, both alone or in fixed-dose combination tablets with chlorthalidone or amlodipine. Beneficial effects of AZI were also noted in patients with any degree of renal impairment. In addition, safety profiles of AZI were similar to that of the placebo. Keywords: hypertension, pharmacology, azilsartan, blood pressure, pharmacokinetics, cost-effectiveness (Source: Core Evidence)
Source: Core Evidence - April 4, 2016 Category: Drugs & Pharmacology Tags: Core Evidence Source Type: research

Azilsartan medoxomil in the management of hypertension
Angeloni E (Source: Core Evidence)
Source: Core Evidence - April 4, 2016 Category: Drugs & Pharmacology Source Type: research

Clinical utility of tadalafil in the treatment of pulmonary arterial hypertension: an evidence-based review
(Source: Core Evidence)
Source: Core Evidence - November 1, 2015 Category: Drugs & Pharmacology Tags: Core Evidence Source Type: research

Clinical utility of tadalafil in the treatment of pulmonary arterial hypertension: an evidence-based review
Adam M Henrie, James J Nawarskas, Joe R Anderson College of Pharmacy, University of New Mexico, Albuquerque, NM, USA Abstract: Pulmonary arterial hypertension (PAH) is a chronic and disabling condition characterized by an elevated pulmonary vascular resistance and an elevated mean pulmonary arterial pressure. Despite recent improvements in treatment availability, PAH remains challenging to treat, burdensome for patients, and ultimately incurable. Tadalafil is a phosphodiesterase-5 inhibitor that is administered once daily by mouth for the treatment of PAH. Current treatment guidelines recommend tadalafil as an option for ...
Source: Core Evidence - November 1, 2015 Category: Drugs & Pharmacology Tags: Core Evidence Source Type: research

Tadalafil in pulmonary arterial hypertension
Henrie AM, Nawarskas JJ, Anderson JR (Source: Core Evidence)
Source: Core Evidence - November 1, 2015 Category: Drugs & Pharmacology Source Type: research

Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis
(Source: Core Evidence)
Source: Core Evidence - August 26, 2015 Category: Drugs & Pharmacology Tags: Core Evidence Source Type: research